
Ranolin XR500 mg
Square Pharmaceuticals PLC.
Ranolazine is an anti-anginal medicine indicated for the treatment of chronic angina (long-term management of stable angina pectoris), not for relief of an acute angina attack.
Ranolazine is an anti-anginal medicine indicated for the treatment of chronic angina (long-term management of stable angina pectoris), not for relief of an acute angina attack.
| Step | Dose |
|---|---|
| Starting dose | 500 mg orally twice daily |
| Titration | May be increased to 1000 mg twice daily based on clinical symptoms and response |
| Maximum dose | 1000 mg twice daily |
Safety and efficacy of Ranolazine have not been established in pediatric patients; it is not recommended for use in this population.
Ranolazine should be used with caution in patients with mild-to-moderate renal impairment, as it has been associated with rare reports of acute kidney injury; it has not been well studied in severe renal impairment and close monitoring is advised (see Precautions and Warnings).
Ranolazine is contraindicated in patients with hepatic cirrhosis (see Contraindications).
The most commonly reported side effects of Ranolazine include:
Less common but clinically important effects include asthenia (weakness), hypotension, dose-related QT interval prolongation, and, rarely, syncope. Patients experiencing fainting, palpitations, severe dizziness, or signs of an allergic reaction while taking Ranolazine should seek prompt medical attention.
Ranolazine is contraindicated in the following situations:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.